Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma has announced its total number of outstanding shares and voting rights as of May 1, 2021. The company has 78,997,540 ordinary shares and 79,792,040 theoretical voting rights, which include preferred shares. The number of exercisable voting rights stands at 79,773,465. This disclosure aims to keep the market informed as per AMF regulations. Innate Pharma is focused on oncology treatments and collaborates with major biopharmaceutical companies.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced its Annual General Meeting (AGM) set for May 28, 2021, at 11:00 a.m. CEST, which will be held virtually due to COVID-19 restrictions. Shareholders can vote by post or proxy before May 25. Written questions may be submitted until May 26. The meeting will be accessible via webcast, with voting results communicated during the session. Innate Pharma is focused on oncology and has a diverse pipeline of antibodies aimed at improving cancer treatment outcomes.

Innate Pharma (IPHA) reported progress in its lacutamab TELLOMAK trial, advancing to Stage 2 for KIR3DL2-expressing mycosis fungoides after positive results. The NK cell engager IPH6101 was selected by Sanofi for further development, triggering a €7 million milestone payment. The company reported a cash position of €181.7 million and revenues of €4.5 million for Q1 2021, down from €19.3 million in the same period last year. Innate expects to present additional data from clinical trials later this year.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced a conference call on May 11, 2021, to discuss Q1 2021 business updates. The call will feature CEO Mondher Mahjoubi, CMO Joyson Karakunnel, and CFO Frédéric Lombard. Interested participants can join via webcast or telephone after registering. Innate Pharma focuses on oncology and boasts a diverse pipeline of therapeutic antibodies designed to improve cancer treatment outcomes. Its partnerships with leading biopharmaceutical companies enhance its research capabilities in this sector.

Innate Pharma has filed its 2020 Universal Registration Document with the French AMF and its annual report on Form 20-F with the SEC. Both documents are accessible on the company's website. Innate focuses on oncology with a pipeline of therapeutic antibodies aimed at improving cancer treatments. The company has established significant alliances with major biopharmaceutical firms, enhancing its research capacity. However, the press release warns of risks associated with R&D, clinical trial uncertainties, and potential impacts from COVID-19 on operations.

Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced the filing of its 2020 Universal Registration Document with the French market authority, AMF, and its annual report on Form 20-F with the SEC. Both documents are available on the company’s and the respective authorities' websites. Innate Pharma is a clinical-stage biotech company focused on oncology, with a diverse pipeline of therapeutic antibodies aimed at improving cancer treatment. The company collaborates with major biopharmaceutical firms, enhancing its market position.

Innate Pharma will hold its Annual General Meeting (AGM) on May 28, 2021, at 11:00 a.m. CET. The meeting will be broadcasted live, allowing shareholders to participate via mail or proxy due to health-related restrictions on gatherings.

Shareholders must register their shares two business days before the AGM to vote. Written questions are welcomed until two business days prior, and connection details will be available on the company’s website. For more information, documentation will be accessible through their investor relations email.

Innate Pharma has disclosed its share capital structure as of April 1, 2021. The company has a total of 78,996,240 ordinary shares outstanding, along with 6,806 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 79,799,621, while 79,781,046 are exercisable. This information complies with the French stock market regulations to ensure market transparency.

Innate Pharma focuses on cancer treatment through therapeutic antibodies and partners with major biopharmaceutical firms.

Innate Pharma reported financial results for 2020, revealing a revenue decline of 17.9% to €70.5 million, attributed mainly to a drop in collaboration income from AstraZeneca. The company faced a net loss of €64 million, up from €20.8 million the previous year, partly due to a €43.5 million impairment on Lumoxiti assets after returning commercialization rights to AstraZeneca. Despite challenges, Innate achieved significant milestones, including PRIME designation for lacutamab and a Phase 3 trial startup for monalizumab, contributing to a cash position of €190.6 million by year-end.